6634 Stock Overview
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases.
Sinew Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$79.80|
|52 Week High||NT$99.00|
|52 Week Low||NT$62.10|
|1 Month Change||-5.00%|
|3 Month Change||-0.50%|
|1 Year Change||-0.75%|
|3 Year Change||179.90%|
|5 Year Change||n/a|
|Change since IPO||60.24%|
Recent News & Updates
Companies Like Sinew Pharma (GTSM:6634) Can Afford To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Sinew Pharma ( GTSM:6634...
Sinew Pharma (GTSM:6634) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Sinew Pharma...
|6634||TW Pharmaceuticals||TW Market|
Return vs Industry: 6634 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: 6634 underperformed the TW Market which returned 0.7% over the past year.
|6634 Average Weekly Movement||5.6%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||4.6%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.1%|
Stable Share Price: 6634 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 6634's weekly volatility (6%) has been stable over the past year.
About the Company
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States.
Sinew Pharma Fundamentals Summary
|6634 fundamental statistics|
Is 6634 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6634 income statement (TTM)|
|Cost of Revenue||NT$1.14m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.33|
|Net Profit Margin||-1,470.14%|
How did 6634 perform over the long term?See historical performance and comparison
Is Sinew Pharma undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6634's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6634's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 6634 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.
PE vs Market: 6634 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6634's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6634 is overvalued based on its PB Ratio (3.5x) compared to the TW Pharmaceuticals industry average (2x).
How is Sinew Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sinew Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Sinew Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6634 is currently unprofitable.
Growing Profit Margin: 6634 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6634 is unprofitable, and losses have increased over the past 5 years at a rate of 2.8% per year.
Accelerating Growth: Unable to compare 6634's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6634 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).
Return on Equity
High ROE: 6634 has a negative Return on Equity (-5.84%), as it is currently unprofitable.
How is Sinew Pharma's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6634's short term assets (NT$1.5B) exceed its short term liabilities (NT$15.1M).
Long Term Liabilities: 6634's short term assets (NT$1.5B) exceed its long term liabilities (NT$850.0K).
Debt to Equity History and Analysis
Debt Level: 6634 is debt free.
Reducing Debt: 6634 has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6634 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6634 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 4.1% each year
What is Sinew Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6634's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6634's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6634's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6634's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6634 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Dr. Kaimin Chu MD, PhD, serves as the Chairman & Chief Executive Officer at Sinew Pharma Inc. Dr. Chu served as Director of the Clinical Research Center and Director of Cardiology at the Tri-Service Genera...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.1%.
Sinew Pharma Inc.'s employee growth, exchange listings and data sources
- Name: Sinew Pharma Inc.
- Ticker: 6634
- Exchange: TPEX
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$5.510b
- Shares outstanding: 69.05m
- Website: https://www.sinewpharma.com
Number of Employees
- Sinew Pharma Inc.
- C516, Building C
- No. 99, Ln. 130
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.